Gudrun Lange

Source: LinkedIn

Gudrun Lange, PhD, is a clinical neuropsychologist who works with Dr. Benjamin Natelson at the Pain & Fatigue Study Center, New York, New York. There she heads studies on brain fog in chronic fatigue syndrome and fibromyalgia.

CFSAC Committee

Dr. Lange is a voting member of the Health and Human Services's Chronic Fatigue Syndrome Advisory Committee for the term 12/13/2017 to 12/12/2021.

Notable studies

• 2017, Multi-Site Clinical Assessment of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (MCAM): Design and Implementation of a Prospective/Retrospective Rolling Cohort Study (Full Text)
• 2017, Multimodal and simultaneous assessments of brain and spinal fluid abnormalities in chronic fatigue syndrome and the effects of psychiatric comorbidity (Full Text)
• 2015, Effect of Milnacipran Treatment on Ventricular Lactate in Fibromyalgia: A Randomized, Double-Blind, Placebo-Controlled Trial (Full Text)
• 2013, Attention network test: assessment of cognitive function in chronic fatigue syndrome
• 2011, Safety and efficacy of vagus nerve stimulation in fibromyalgia: a phase I/II proof of concept trial
• 2005, Objective evidence of cognitive complaints in Chronic Fatigue Syndrome: a BOLD fMRI study of verbal working memory (Abstract)
• 2004, Cognitive Function Index for Patients with Chronic Fatigue Syndrome
• 2002, A status report on chronic fatigue syndrome (Full Text)
• 22001, Health-Related Personality Variables in Chronic Fatigue Syndrome and Multiple Sclerosis (Abstract)

Clinic location

Phillips Ambulatory Care Center, Suite 5D

Beth Israel Medical Center

10 Union Square East

New York, NY 10003-3314

Talks and interviews

11 April 2012, "Cognition & CFS: What Do We Know?" by the CFIDS Association of America with speakers Gudren Lange and Suzanne Vernon, introduced by Kim McCleary

• 2009, 9th International IACFS/ME Research and Clinical Conference: Talk Title - Assessing ME/CFS Brain Functioning

Online presence

• PubMed
• Pain & Fatigue Study Center Bio Page
• LinkedIn

Learn more

• Pain & Fatigue Study Center Homepage

See also

• Benjamin Natelson

Chronic Fatigue Syndrome Advisory Committee (CFSAC) - (sometimes pronounced SIF-SACK) A US government advisory council that met twice per year, covering current topics related to Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. Meetings usually lasted for two days and the results were presented to the Secretary of Health and Human Services (HHS). After 15 years, on September 5, 2018, CFSAC's charter was not renewed by the Department of HHS, effectively dissolving the committee without notice or warning.

cognition Thought processes, including attention, reasoning, and memory.

phase one A drug trial involving only a small group of humans, often healthy volunteers, to assess drug safety and side effects. Typically 20-80 participants, often using a comparison group.

cognition Thought processes, including attention, reasoning, and memory.

myalgic encephalomyelitis (M.E.) - A disease often marked by neurological symptoms, but fatigue is sometimes a symptom as well. Some diagnostic criteria distinguish it from chronic fatigue syndrome, while other diagnostic criteria consider it to be a synonym for chronic fatigue syndrome. A defining characteristic of ME is post-exertional malaise (PEM), or post-exertional neuroimmune exhaustion (PENE), which is a notable exacerbation of symptoms brought on by small exertions. PEM can last for days or weeks. Symptoms can include cognitive impairments, muscle pain (myalgia), trouble remaining upright (orthostatic intolerance), sleep abnormalities, and gastro-intestinal impairments, among others. An estimated 25% of those suffering from ME are housebound or bedbound. The World Health Organization (WHO) classifies ME as a neurological disease.

double blinded trial A clinical trial is double blinded if neither the participants nor the researchers know which treatment group they are allocated to until after the results are interpreted. This reduces bias. (Learn more: www.nottingham.ac.uk)